A public health response to opioid use in pregnancy

Pediatrics

Volumn 139, Issue 3, 2017, Pages

  Patrick, Stephen W ^a,b,c   Schiff, Davida M ^d   Ryan, Sheryl A ^e   Quigley, Joanna ^e   Gonzalez, Pamela K ^e   Walker, Leslie R ^e  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; METHADONE; NARCOTIC ANALGESIC AGENT;

ALCOHOL CONSUMPTION; ARTICLE; CHILD WELFARE; CONTRACEPTION; CRIMINAL JUSTICE; DRUG SCREENING; EARLY DIAGNOSIS; FUNDING; HEALTH CARE ACCESS; HUMAN; INFORMED CONSENT; NEONATAL ABSTINENCE SYNDROME; OBSTETRIC PROCEDURE; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIMARY PREVENTION; PUBLIC HEALTH SERVICE; SOCIAL WORK; UNPLANNED PREGNANCY; URINALYSIS; CHILD; CHILD ADVOCACY; DRUG DEPENDENCE TREATMENT; FEMALE; HEALTH CARE DELIVERY; LEGISLATION AND JURISPRUDENCE; NEWBORN; OPIOID-RELATED DISORDERS; PREGNANCY COMPLICATIONS; PRENATAL CARE; SUBSTANCE ABUSE; UNITED STATES;

CHILD; CHILD ADVOCACY; CHILD WELFARE; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; INFANT, NEWBORN; OPIOID-RELATED DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL CARE; PRIMARY PREVENTION; SUBSTANCE ABUSE DETECTION; SUBSTANCE ABUSE TREATMENT CENTERS; UNITED STATES;

EID: 85016029675     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2016-4070     Document Type: Article

References (71)

1. Young N, Gardner S, Otero C, et al.. Substance-exposed infants: state responses to the problem. HHS Publication SMA09-4369. Available at: https://ncsacw.samhsa.gov/files/Substance-Exposed-Infants.pdf.AccessedAugust23,2016
2. Patrick SW, Davis MM, Lehmann CU, Cooper WO. Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012 [published erratum appears in J Perinatol. 2015;35(8):667]. J Perinatol. 2015;35(8):650-655
3. Patrick SW, Dudley J, Martin PR, et al.. Prescription opioid epidemic and infant outcomes. Pediatrics. 2015;135(5):842-850
4. Ailes EC, Dawson AL, Lind JN, et al.; Centers for Disease Control and Prevention. Opioid prescription claims among women of reproductive age-United States, 2008-2012. MMWR Morb Mortal Wkly Rep. 2015;64(2):37-41
5. Epstein RA, Bobo WV, Martin PR, et al.. Increasing pregnancy-related use of prescribed opioid analgesics. Ann Epidemiol. 2013;23(8):498-503
6. Desai RJ, Hernandez-Diaz S, Bateman BT, Huybrechts KF. Increase in prescription opioid use during pregnancy among Medicaidenrolled women. Obstet Gynecol. 2014;123(5):997-1002
7. Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA. 2012;307(18):1934-1940
8. Office of National Drug Control Policy. Epidemic: responding to America's prescription drug abuse crisis. Washington, DC: Office of National Drug Control Policy; 2011. Available at: https://www.whitehouse.gov/sites/default/files/ondcp/policy-andresearch/rx-abuse-plan.pdf.AccessedAugust23,2016
9. American Academy of Family Physicians. Position paper: preconception care. Leawood, KS: American Academy of Family Physicians; 2015. Available at: www.aafp.org/about/policies/all/preconception-care.html.AccessedAugust23,2016
10. Heil SH, Jones HE, Arria A, et al.. Unintended pregnancy in opioidabusing women. J Subst Abuse Treat. 2011;40(2):199-202
11. Winner B, Peipert JF, Zhao Q, et al.. Effectiveness of long-acting reversible contraception. N Engl J Med. 2012;366(21):1998-2007
12. American Academy of Family Physicians. Policy: long-acting reversible contraceptives. Leawood, KS: American Academy of Family Physicians; 2015. Available at: www.aafp.org/about/policies/all/longactingreversiblecontraceptives.html.AccessedAugust 23, 2016
13. American College of Obstetricians and Gynecologists Committee on Practice Bulletins-Gynecology. Practice bulletin: long-acting reversible contraception: implants and intrauterine devices. Washington, DC: American College of Obstetricians and Gynecologists; 2011. Available at: www.acog.org/Resources-And-Publications/Practice-Bulletins/Committee-on-Practice-Bulletins-Gynecology/Long-Acting-Reversible-Contraception-Implants-and-Intrauterine-Devices.AccessedAugust 23, 2016
14. Moniz MH, Chang T, Davis MM, Forman J, Landgraf J, Dalton VK. Medicaid administrator experiences with the implementation of immediate postpartum long-acting reversible contraception. Womens Health Issues. 2016;26(3):313-320
15. Wright TE, Terplan M, Ondersma SJ, et al.. The role of screening, brief intervention, and referral to treatment in the perinatal period. Am J Obstet Gynecol. 2016;215(5):539-547
16. ACOG Committee on Health Care for Underserved Women; American Society of Addiction Medicine. ACOG Committee Opinion No. 524: opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol. 2012;119(5):1070-1076
17. ChasnoffIJ, Wells AM, McGourty RF, Bailey LK. Validation of the 4P's Plus screen for substance use in pregnancy validation of the 4P's Plus. J Perinatol. 2007;27(12):744-748
18. Goodman DJ, WolffKB. Screening for substance abuse in women's health: a public health imperative. J Midwifery Womens Health. 2013;58(3):278-287
19. American College of Obstetricians and Gynecologists. Committee Opinion No. 633: alcohol abuse and other substance use disorders: ethical issues in obstetric and gynecologic practice. Obstet Gynecol. 2015;125(6):1529-1537
20. ChasnoffIJ, Landress HJ, Barrett ME. The prevalence of illicit-drug or alcohol use during pregnancy and discrepancies in mandatory reporting in Pinellas County, Florida. N Engl J Med. 1990;322(17):1202-1206
21. Kerker BD, Horwitz SM, Leventhal JM. Patients' characteristics and providers' attitudes: predictors of screening pregnant women for illicit substance use. Child Abuse Negl. 2004;28(2):209-223
22. Kunins HV, Bellin E, Chazotte C, Du E, Arnsten JH. The effect of race on provider decisions to test for illicit drug use in the peripartum setting. J Womens Health (Larchmt). 2007;16(2):245-255
23. Roberts SC, Nuru-Jeter A. Women's perspectives on screening for alcohol and drug use in prenatal care. Womens Health Issues. 2010;20(3):193-200
24. Wexelblatt SL, Ward LP, Torok K, Tisdale E, Meinzen-Derr JK, Greenberg JM. Universal maternal drug testing in a high-prevalence region of prescription opiate abuse. J Pediatr. 2015;166(3):582-586
25. US Preventive Services Task Force. Final recommendation statement: drug use, illicit: screening. Rockville, MD: US Preventive Services Task Force; 2008. Available at: www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/druguse-illicit-screening.AccessedAugust23,2016
26. Levy S, Siqueira LM, Ammerman SD, et al.; Committee on Substance Abuse. Testing for drugs of abuse in children and adolescents. Pediatrics. 2014;133(6). Available at:www.pediatrics.org/cgi/content/full/133/6/e1798
27. Goler NC, Armstrong MA, Taillac CJ, Osejo VM. Substance abuse treatment linked with prenatal visits improves perinatal outcomes: a new standard. J Perinatol. 2008;28(9):597-603
28. El-Mohandes A, Herman AA, Nabil El-Khorazaty M, Katta PS, White D, Grylack L. Prenatal care reduces the impact of illicit drug use on perinatal outcomes. J Perinatol. 2003;23(5):354-360
29. Armstrong MA, Gonzales Osejo V, Lieberman L, Carpenter DM, Pantoja PM, Escobar GJ. Perinatal substance abuse intervention in obstetric clinics decreases adverse neonatal outcomes. J Perinatol. 2003;23(1):3-9
30. Lieberman L, Taillac C, Goler N. Vision, research, innovation and influence: Early Start's 15-year journey from pilot project to regional program. Perm J. 2005;9(1):62-64
31. Davis KJ, Yonkers KA. Making lemonade out of lemons: a case report and literature review of external pressure as an intervention with pregnant and parenting substance-using women. J Clin Psychiatry. 2012;73(1):51-56
32. Guttmacher Institute. Substance abuse during pregnancy. State Policies in Brief. December 1, 2015. Available at: www.guttmacher.org/statecenter/spibs/spib-SADP.pdf.AccessedAugust23,2016
33. Terplan M, Longinaker N, Appel L. Women-centered drug treatment services and need in the United States, 2002-2009. Am J Public Health. 2015;105(11):e50-e54
34. Greenfield SF, Rosa C, Putnins SI, et al.. Gender research in the National Institute on Drug Abuse National Treatment Clinical Trials Network: a summary of findings. Am J Drug Alcohol Abuse. 2011;37(5):301-312
35. Liebschutz J, Savetsky JB, Saitz R, Horton NJ, Lloyd-Travaglini C, Samet JH. The relationship between sexual and physical abuse and substance abuse consequences. J Subst Abuse Treat. 2002;22(3):121-128
36. McHugo GJ, Caspi Y, Kammerer N, et al.. The assessment of trauma history in women with co-occurring substance abuse and mental disorders and a history of interpersonal violence. J Behav Health Serv Res. 2005;32(2):113-127
37. Substance Abuse and Mental Health Services Administration. Substance abuse treatment: addressing the specific needs of women. A Treatment Improvement Protocol (TIP 51). Publication SMA 13-4426. Rockville, MD: US Department of Health and Human Services; 2009. Available at: https://store.samhsa.gov/shin/content/SMA13-4426/SMA13-4426.pdf.AccessedAugust23,2016
38. Greenfield SF, Brooks AJ, Gordon SM, et al.. Substance abuse treatment entry, retention, and outcome in women: a review of the literature. Drug Alcohol Depend. 2007;86(1):1-21
39. Brady TM. Women in Substance Abuse Treatment: Results From the Alcohol and Drug Services Study (ADSS). Rockville, MD: Substance Abuse and Mental Health Services Administration, Office of Applied Studies; 2005
40. Gregoire KA, Schultz DJ. Substanceabusing child welfare parents: treatment and child placement outcomes. Child Welfare. 2001;80(4):433-452
41. Nishimoto RH, Roberts AC. Coercion and drug treatment for postpartum women. Am J Drug Alcohol Abuse. 2001;27(1):161-181
42. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;3:CD002209
43. Jones HE, Heil SH, Baewert A, et al.. Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction. 2012;107(suppl 1):5-27
44. Minozzi S, Amato L, Bellisario C, Ferri M, Davoli M. Maintenance agonist treatments for opiate-dependent pregnant women. Cochrane Database Syst Rev. 2013;12:CD006318
45. Ordean A, Kahan M, Graves L, Abrahams R, Kim T. Obstetrical and neonatal outcomes of methadonemaintained pregnant women: a Canadian multisite cohort study. J Obstet Gynaecol Can. 2015;37(3):252-257
46. Burns L, Mattick RP, Lim K, Wallace C. Methadone in pregnancy: treatment retention and neonatal outcomes. Addiction. 2007;102(2):264-270
47. Hudak ML, Tan RC; Committee on Drugs; Committee on Fetus and Newborn. Clinical report: neonatal drug withdrawal. Pediatrics. 2012;129(2). Available at: www.pediatrics.org/cgi/content/full/129/2/e540
48. Paltrow LM, Flavin J. Arrests of and forced interventions on pregnant women in the United States, 1973-2005: implications for women's legal status and public health. J Health Polit Policy Law. 2013;38(2):299-343
49. Committee on Substance Abuse. Drugexposed infants [policy statement]. Pediatrics. 1990;86(4):639-642
50. Committee on Substance Abuse. Drugexposed infants. Pediatrics. 1995;96(2 pt 1):364-367
51. American College of Obstetricians and Gynecologists Committee on Health Care for Underserved Women. AGOG Committee Opinion No. 473: substance abuse reporting and pregnancy: the role of the obstetrician-gynecologist. Obstet Gynecol. 2011;117(1):200-201
52. American Academy of Family Physicians. Policy: substance Abuse and Addition. Pregnant women, substance use and abuse by. Available at: www.aafp.org/about/policies/all/substance-abuse.html#pregnant.AccessedAugust23,2016
53. Cole HM. Legal interventions during pregnancy: court-ordered medical treatments and legal penalties for potentially harmful behavior by pregnant women. JAMA. 1990;264(20):2663-2670
54. American Public Health Association. Illicit drug use by pregnant women. Washington, DC: American Public Health Association; 1990. Available at: https://www.apha.org/policiesand-advocacy/public-health-policystatements/policy-database/2014/07/03/10/56/illicit-drug-use-by-pregnantwomen.AccessedAugust23,2016
55. American Nurses Association, Center for Ethics and Human Rights. Position statement: non-punitive alcohol and drug treatment for pregnant and breast feeding women and their exposed children. Washington, DC: American Nurses Association; 2011. Available at: www.nursingworld.org/MainMenuCategories/EthicsStandards/Ethics-Position-Statements/Nonpunitive-Alcohol-and-Drug-Treatmentfor-Pregnant-and-Breast-feeding-Women-and-the-Exposed-Childr.pdf.AccessedAugust23,2016
56. American Psychiatric Association, Board of Trustees. Position statement on care of pregnant and newly delivered women addicts. Washington, DC: American Psychiatric Association; 2007. Available at: www.psychiatry.org/File%20Library/About-APA/Organization-Documents-Policies/Policies/Position-2007-Pregnant-Addiction.pdf.AccessedAugust23,2016
57. American Society of Addiction Medicine, Board of Directors. Chemically dependent women and pregnancy. Chevy Chase, MD: American Society of Addiction Medicine; 1989. Available at: www.asam.org/advocacy/find-a-policy-statement/view-policystatement/public-policy-statements/2011/12/16/chemically-dependentwomen-and-pregnancy.AccessedAugust23,2016
58. Criminalization of pregnant women with substance use disorders. J Obstet Gynecol Neonatal Nurs. 2015;44(1):155-157
59. March of Dimes. Policies and programs to address drug-exposed newborns. White Plains, NY: March of Dimes; 2014. Available at:www.marchofdimes.org/materials/NASPolicy-Fact-Sheet-December-2014.pdf.AccessedAugust23,2016
60. National Perinatal Association. Position paper: substance abuse among pregnant women. Lonedell, MO: National Perinatal Association; June 2012. Available at:www.nationalperinatal.org/resources/Documents/Substance%20Abuse%20Among%20Pregnant%20Women%20Position%20Paper%2010-1-15.pdf.AccessedAugust23,2016
61. Lester BM, Andreozzi L, Appiah L. Substance use during pregnancy: time for policy to catch up with research. Harm Reduct J. 2004;1(1):5
62. Tennessee Senate Bill 1391 by Tate, House Bill 1295 by Weaver (2013). An Act to amend Tennessee code annotated title 39, relative to criminal law. Available at:www.capitol.tn.gov/Bills/108/Bill/SB1391.pdf.AccessedAugust23,2016
63. North Carolina Senate Bill 297 (2015). Prenatal narcotic drug use/criminal offense. Available at: www. ncleg. net/ Sessions/2015/Bills/Senate/PDF/ S297v1. pdf. Accessed August 23, 2016
64. Roberts SC, Pies C. Complex calculations: how drug use during pregnancy becomes a barrier to prenatal care. Matern Child Health J. 2011;15(3):333-341
65. Jessup M, Humphreys J, Brindis C, Lee K. Extrinsic barriers to substance abuse treatment among pregnant drug dependent women. J Drug Issues. 2003;33(2):285-304
66. Schempf AH, Strobino DM. Drug use and limited prenatal care: an examination of responsible barriers. Am J Obstet Gynecol. 2009;200(4):412. e1-412.e10
67. Poland ML, Dombrowski MP, Ager JW, Sokol RJ. Punishing pregnant drug users: enhancing the flight from care. Drug Alcohol Depend. 1993;31(3):199-203
68. Maupin R Jr, Lyman R, Fatsis J, et al.. Characteristics of women who deliver with no prenatal care. J Matern Fetal Neonatal Med. 2004;16(1):45-50
69. The Child Abuse Prevention and Treatment Act. 2010, as amended by Pub L No. 111-320, the CAPTA Reauthorization Act of 2010. Available at: https://www.acf.hhs.gov/sites/default/files/cb/capta2010.pdf.AccessedAugust23,2016
70. Stoltzfus E. Child welfare: an overview of federal programs and their current funding. Washington, DC: Congressional Research Service; 2015, Available at: https://www.fas.org/sgp/crs/misc/R43458.pdf.AccessedAugust23,2016
71. França UL, Mustafa S, McManus ML. The growing burden of neonatal opiate exposure on children and family services in Massachusetts. Child Maltreat. 2016;21(1):80-84